See more : NGEx Minerals Ltd. (NGXXF) Income Statement Analysis – Financial Results
Complete financial analysis of Silo Pharma, Inc. (SILO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silo Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Patel Integrated Logistics Limited (PATINTLOG.BO) Income Statement Analysis – Financial Results
- Safety Shot Inc (SHOT) Income Statement Analysis – Financial Results
- Tyme Technologies, Inc. (TYME) Income Statement Analysis – Financial Results
- QC Holdings, Inc. (QCCO) Income Statement Analysis – Financial Results
- Oxford Square Capital Corp. 5.50% Notes due 2028 (OXSQG) Income Statement Analysis – Financial Results
Silo Pharma, Inc. (SILO)
About Silo Pharma, Inc.
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.10K | 72.10K | 71.26K | 40.92K | 40.57K | 0.00 | 847.41K | -669.48K | -145.19K | -107.11K | 105.52K | 0.00 | 0.00 |
| Cost of Revenue | 5.84K | 5.84K | 5.00K | 176.13K | 27.39K | 17.55K | 0.00 | 0.00 | 0.00 | -127.68K | 104.90K | 0.00 | 0.00 |
| Gross Profit | 66.26K | 66.26K | 66.26K | -135.20K | 13.18K | -17.55K | 847.41K | -669.48K | -145.19K | 20.57K | 625.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 91.90% | 91.90% | 92.98% | -330.38% | 32.49% | 0.00% | 100.00% | 100.00% | 100.00% | -19.20% | 0.59% | 0.00% | 0.00% |
| Research & Development | 845.09K | 1.29M | 693.91K | 88.80K | 63.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.08M | 2.43M | 2.27M | 2.18M | 864.18K | 459.83K | 313.37K | 300.99K | 167.70K | 269.44K | 72.61K | 39.45K | 49.80K |
| Selling & Marketing | 0.00 | -1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.08M | 2.43M | 2.27M | 2.18M | 864.18K | 459.83K | 313.37K | 300.99K | 167.70K | 269.44K | 72.61K | 39.45K | 49.80K |
| Other Expenses | 0.00 | 2.17M | 1.95M | 3.00K | 765.72K | 314.61K | 177.50K | 142.50K | 96.61K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.92M | 3.71M | 2.96M | 2.27M | 927.65K | 459.83K | 490.87K | 443.49K | 264.31K | 269.44K | 72.61K | 39.45K | 49.80K |
| Cost & Expenses | 3.93M | 3.72M | 2.96M | 2.45M | 955.03K | 459.83K | 427.96K | 443.49K | 264.31K | 269.44K | 72.61K | 39.45K | 49.80K |
| Interest Income | 398.53K | 72.64K | 1.21K | 11.54K | 12.20K | 4.22K | 20.48K | 49.84K | 40.34K | 20.57K | 625.00 | 0.00 | 0.00 |
| Interest Expense | 4.87K | 2.20K | 3.04K | 269.27K | 62.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 229.38K | 72.64K | -147.29K | 179.92K | 28.14K | 17.55K | -701.10K | 719.32K | 192.33K | 127.68K | -104.90K | 0.00 | 0.00 |
| EBITDA | -3.63M | -3.91M | 4.19M | -2.39M | -930.40K | -951.91K | 0.00 | 0.00 | -217.17K | -248.87K | -71.99K | -39.45K | -49.80K |
| EBITDA Ratio | -5,029.28% | -4,958.28% | -4,057.63% | -5,847.68% | -2,224.03% | 0.00% | -138.24% | -48.64% | 17.11% | 113.14% | -167.63% | 0.00% | 0.00% |
| Operating Income | -3.86M | -3.65M | -2.74M | -2.57M | -930.40K | -594.24K | -470.39K | -393.66K | -217.17K | -248.87K | -71.99K | -39.45K | -49.80K |
| Operating Income Ratio | -5,347.41% | -5,059.02% | -3,850.95% | -6,287.34% | -2,293.38% | 0.00% | -55.51% | 58.80% | 149.58% | 232.34% | -68.22% | 0.00% | 0.00% |
| Total Other Income/Expenses | 224.51K | -279.73K | 6.93M | -464.55K | -82.89K | -375.22K | 826.92K | -719.32K | -192.33K | 0.00 | 104.90K | 0.00 | 0.00 |
| Income Before Tax | -3.63M | -3.91M | 4.18M | -3.04M | -1.01M | -969.46K | 356.54K | -1.11M | -409.50K | -376.55K | 32.91K | -39.45K | -49.80K |
| Income Before Tax Ratio | -5,036.04% | -5,419.25% | 5,868.30% | -7,422.52% | -2,497.71% | 0.00% | 42.07% | 166.24% | 282.05% | 351.54% | 31.19% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.16K | 24.88K | 92.35K | 34.79K | -513.85K | -62.91K | 696.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -3.70M | -3.91M | 3.90M | -3.13M | -1.05M | -969.46K | 356.54K | -1.11M | -409.50K | -376.55K | 32.91K | -39.45K | -49.80K |
| Net Income Ratio | -5,132.57% | -5,420.86% | 5,477.86% | -7,648.18% | -2,583.47% | 0.00% | 42.07% | 166.24% | 282.05% | 351.54% | 31.19% | 0.00% | 0.00% |
| EPS | -1.20 | -1.71 | 2.06 | -2.37 | -1.24 | -0.99 | 0.50 | -1.11 | -0.40 | -0.39 | 0.05 | -0.06 | -0.08 |
| EPS Diluted | -1.20 | -1.71 | 2.03 | -2.37 | -1.24 | -0.99 | 0.50 | -1.11 | -0.40 | -0.39 | 0.05 | -0.06 | -0.08 |
| Weighted Avg Shares Out | 3.08M | 2.28M | 1.90M | 1.32M | 842.30K | 982.03K | 1.00M | 1.00M | 1.01M | 958.30K | 648.74K | 612.62K | 612.62K |
| Weighted Avg Shares Out (Dil) | 3.08M | 2.28M | 1.92M | 1.32M | 842.30K | 982.03K | 1.04M | 1.00M | 1.01M | 958.30K | 648.74K | 612.62K | 612.62K |
Silo Pharma To Appear On National Media Broadcast on Psychedelics
Englewood Cliffs, NJ , July 21, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, has announced that the company will be participating in a nationwide media...
Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore
Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis Next steps include targeted approach to delivering Psychedelics including Psilocybin and Ketamine Englewood Cliffs NJ, July 09, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC QB: SILO), a...
Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore
Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis Next steps include targeted approach to delivering Psychedelics including Psilocybin and Ketamine Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis Next steps include targeted...
Silo Pharma extends agreement for experimental Rheumatoid Arthritis nanoparticle homing peptide
Englewood Cliffs NJ, July 07, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC QB: SILO), a developmental stage biopharmaceutical company, today announced that it has extended its exclusive option agreement with the University of Maryland, Baltimore to explore a novel...
Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson's and Bipolar Patients
Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has entered into a Scientific Research Agreement (SRA)...
Silo Pharma Submits Application for NASDAQ up-listing
Englewood Cliffs, NJ, May 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has submitted its initial application to...
Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson's disease has been submitted for ethics board review.
Englewood Cliffs, NJ, May 13, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that its investigator led study using Psilocybin to treat Parkinson's...
Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI's Z-pod™ technology for the transdermal time released delivery of therapeutics
Sustained Transdermal Delivery Method May Be Key for Alzheimer's and Parkinson's Patients with Dysphagia (difficulty swallowing) Sustained Transdermal Delivery Method May Be Key for Alzheimer's and Parkinson's Patients with Dysphagia (difficulty swallowing)
Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ
Englewood Cliffs, NJ, April 22, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has unanimously voted to uplist...
Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology
Agreement to explore the use of Silo Pharma's Novel Peptide
Source: https://incomestatements.info
Category: Stock Reports